NYSEAMERICAN:SYN Synthetic Biologics (SYN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Synthetic Biologics Stock (NYSEAMERICAN:SYN) Get Synthetic Biologics alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,700 shsAverage Volume197,338 shsMarket Capitalization$16.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Synthetic Biologics, Inc. was a clinical-stage biotechnology company focused on developing therapies that address diseases involving the microbiome, gastrointestinal system and mucosal tissues. Its research programs were designed to use engineered probiotics, microbial-based therapeutics and other biologic approaches to treat or prevent disease. The company’s historical pipeline included SYN-010, an investigational therapy for constipation-predominant irritable bowel syndrome; SYN-004 (ribaxamase), an oral enzyme intended to reduce antibiotic-associated disruption of the gut microbiome; and SYN-020, an oral intestinal alkaline phosphatase program investigated for gastrointestinal and metabolic disorders. These candidates were experimental and subject to clinical and regulatory evaluation. In 2021, Synthetic Biologics changed its name to Theriva Biologics, Inc. and began trading under the symbol TOVX. Accordingly, information associated with the SYN symbol generally relates to the company’s former name and earlier development programs. The company’s work was primarily focused on advancing microbiome-based medicines rather than commercial products or services.AI Generated. May Contain Errors. Read More Receive SYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYN Stock News HeadlinesSynthetic Biology Market Size, Share, Growth, Trends, Applications, Competitive Landscape, and Forecast, 2026 to 2034 | 17.6% CAGR Fuels AI-Driven Biomanufacturing OpportunitiesSeptember 30, 2026 | finance.yahoo.comChina Cell Culture Microcarrier Consumables Market Poised for Strong Growth Through 2031, Led by Biologics Demand, Synthetic Microcarriers and Biopharmaceutical ApplicationsSeptember 29, 2026 | finance.yahoo.comNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafer-scale chip that does in minutes what current AI needs days to finish. Unlike conventional chips cut from silicon wafers, this technology uses the entire wafer as one giant chip, running on a fraction of the power. Gilder won't name the company publicly, but he's ready to hand it over.October 10 at 1:00 AM | Eagle Publishing (Ad)Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and ...August 19, 2026 | finance.yahoo.comIsto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBoneAugust 4, 2026 | finance.yahoo.comVivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care SolutionsJuly 21, 2026 | markets.businessinsider.comStudy Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass AloneJanuary 26, 2026 | marketwatch.comMTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™January 15, 2026 | uk.finance.yahoo.comSee More Headlines SYN Stock Analysis - Frequently Asked Questions How were Synthetic Biologics' earnings last quarter? Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) posted its earnings results on Tuesday, November, 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.10. When did Synthetic Biologics' stock split? Synthetic Biologics's stock reverse split on Monday, July 25th 2022.The 1-10 reverse split was announced on Monday, July 25th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Synthetic Biologics? Shares of SYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Synthetic Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Synthetic Biologics investors own include Tonix Pharmaceuticals (TNXP), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Palatin Technologies (PTN) and Meta Platforms (META). Company Calendar Last Earnings11/02/2021Today10/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:SYN CIK894158 Webwww.syntheticbiologics.com Phone(301) 417-4364Fax301-417-4367Employees16Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.14% Return on Assets-22.74% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.95 per share Price / BookN/AMiscellaneous Outstanding Shares15,844,000Free Float15,503,000Market Cap$16.16 million OptionableNot Optionable Beta1.38 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NYSEAMERICAN:SYN) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synthetic Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synthetic Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
